PathAI, Summit Clinical partner for NASH trial services

By The Science Advisory Board staff writers

September 22, 2021 -- PathAI recently entered a partnership with Summit Clinical Research to launch a clinical trial services solution for developers of drugs to treat nonalcoholic steatohepatitis (NASH).

The collaboration will leverage PathAI's artificial intelligence (AI) tools that are used to evaluate liver pathology and Summit's expertise in NASH drug development and accelerated study execution.

PathAI and Summit Clinical Research will provide sponsors with an offering that features trial design; site activation and patient enrollment; and wet lab, diagnostic, and AI-pathology deployment services, the companies said.

The companies announced that they have contracted with a sponsor to provide pathology services for a phase II clinical trial, with several additional trials that are currently under negotiation.

Copyright © 2021

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter